Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

Prostate cancer screening compares favorably to screening for breast cancer in identifying significant cancers, reducing ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation ...

Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have ...

The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a presentation by Dr. Jozefina Casuscelli discussing the optimal management of de-novo ...

Among prostate cancer patients under active surveillance, low testosterone levels were associated with a statistically significant increased risk of "extreme" progression to grade group 3 or higher ...

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy in prostate cancer Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In ...

Recognising these subtle body changes can lead to an earlier diagnosis, when treatment is more likely to be successful ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...